



INFLUENZA AND PNEUMOCOCCAL VACCINES CLINICAL PRACTICE GUIDELINE

<i>Influenza Vaccine</i>	
The following guideline provides recommendations for members who should receive the Influenza vaccine.	
Individuals who should receive the vaccine:	<ul style="list-style-type: none"> • All people including 65 years of age or older • People with chronic health conditions i.e. heart disease, COPD
Frequency:	<ul style="list-style-type: none"> • Yearly doses are recommended
<i>Pneumococcal Vaccine</i>	
The following guideline provides recommendations for members who should receive pneumococcal vaccine.	
Individuals who should receive the vaccine:	<ul style="list-style-type: none"> • Adults 65 years and older.
Recommendations	<ul style="list-style-type: none"> • Adults 65 or older that have never received a pneumococcal vaccine, should receive either one dose of PVC20 (pneumococcal conjugate vaccine) or one dose of PCV15 followed by a dose of PPSV23 (pneumococcal poly saccharide vaccine) • Adults who previously received PCV13 (but not PCV15, PCV20, or PCV21) at any age and PPSV23 before age 65: Are eligible for PCV20 or PCV21, ideally at least 5 years after the last pneumococcal vaccination. • Adults who previously received both PCV13 and PPSV23, and the PPSV23 was given at or after age 65: Are eligible for PCV20 or PCV21, ideally at least 5 years after the last pneumococcal vaccination, or they should receive a single, final dose of PPCV23, again at least 5 years after the last dose. • Adults who only received PCV13 (and no other pneumococcal vaccines): Can receive PCV20 or PCV21 at least 1 year after the PCV13 dose, or they can receive PPSV23.
This guideline is based on cdc.gov/flu/prevent/vaccinations.htm , and cdc.gov/pneumococcal/vaccination.html	
Revised and approved by QIC 07/29/2025	